[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antiplatelet-drugs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antiplatelet-drugs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100550755","phase-4-indobufen-versus-aspirin-after-coronary-drug-eluting-stent-implantation-in-elderly-patients-with-acute-coronary-syndrome-100550755",false,"NCT06451198","IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome","OPTION2","Inclusion Criteria:\n\n* Age over 65 years old\n* Diagnosed with acute coronary syndrome (unstable angina\u002F non-ST elevation myocardial infarction\u002F ST elevation myocardial infarction)\n* Treated with at least 1 DES implanted in the coronary lesion\n* Receiving dual antiplatelet therapy (aspirin plus ticagrelor)\n* Agree to attend the trial\n\nExclusion Criteria:\n\n* Elective surgical procedure planned within 12 months\n* Life expectancy ≤1 year\n* Known allergy or intolerance to aspirin, ticagrelor or nonsteroidal anti-inflammatory drugs (NSAIDs)\n* History of cerebral hemorrhage\n* History of stroke in six months\n* Active bleeding\n* Known relevant hematological deviations\n* Known, clinically important thrombocytopenia (i.e., \\\u003C100\\*10\\^9\u002FL) or anemia (i.e., \\\u003C90g\u002FL)\n* Active cancer\n* Concomitant use of oral anticoagulants\n* Active participation in another clinical study\n* Other situations in which the investigator considers unsuitable to attend the study","ALL","65 Years",{"count":19,"type":20},2846,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy (DAPT) (indobufen 100mg bid plus ticagrelor 90mg bid) or conventional DAPT (aspirin 100mg qd plus ticagrelor 90mg bid) in acute coronary syndrome (ACS) patients aged over 65 years old undergoing coronary drug-eluting stent (DES) implantation.",[26,27],"Coronary Artery Disease","Antiplatelet Drugs","RECRUITING","2026-03-11",{"date":31,"type":32},"2026-03-12","ACTUAL",{"date":34,"type":32},"2025-05-19",{"date":36,"type":20},"2028-12-31",{"name":38,"class":39},"Shanghai Zhongshan Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100602602","gastrointestinal-bleeding-is-blood-loss-in-the-digestive-tract-classified-as-upper-or-lower-ischemic-heart-disease-is-due-to-blocked-heart-arteries-antiplatelet-drugs-help-prevent-heart-attacks-but-increase-gi-bleeding-risk-especially-when-used-together-as-dual-therapy-100602602","NCT07125651","Gastrointestinal Bleeding is Blood Loss in the Digestive Tract, Classified as Upper or Lower. Ischemic Heart Disease is Due to Blocked Heart Arteries. Antiplatelet Drugs Help Prevent Heart Attacks But Increase GI Bleeding Risk, Especially When Used Together as Dual Therapy.","Prevalence of Gastrointestinal Bleeding in Ischemic Heart Disease Patients Undergoing Single Compared to Dual Antiplatelet Treatment","Inclusion Criteria:\n\n* Patients (aged 18 years old and older) who were diagnosed ischemic heart disease on single or dual antiplatelet therapy and developed gastrointestinal bleeding (manifestation of hematemesis, melena or bleeding per rectum).\n\nExclusion Criteria:\n\n* Patients on anticoagulant.\n* Patients with bleeding tendencies.\n* Individuals with other comorbidities.\n* patients with acute coronary syndrome.\n* Uncooperative patients.","18 Years",{"count":50,"type":20},112,"OBSERVATIONAL","Gastrointestinal bleeding is blood loss in the digestive tract, classified as upper or lower. Ischemic heart disease is due to blocked heart arteries. Antiplatelet drugs help prevent heart attacks but increase GI bleeding risk, especially when used together as dual therapy. This study aims to compare the prevalence and risk of gastrointestinal bleeding in ischemic heart disease patients on single versus dual antiplatelet therapy, and to explore strategies for reducing gastrointestinal bleeding in these patients, enhancing treatment safety without compromising cardiovascular protection.",[54,55,27,56],"Gastro Intestinal Bleeding","Ischaemic Heart Diseases","Antiplatelet Drug-related Gastrointestinal Injury",[58,59,60,61,62,63,64],"Gastrointestinal bleeding","GIB","ischemic heart disease","IHD","Antiplatelet therapy","SAPT","DAPT","NOT_YET_RECRUITING","2025-08-10",{"date":68,"type":32},"2025-08-15",{"date":70,"type":20},"2025-09-01",{"date":72,"type":20},"2026-10",{"name":74,"class":39},"Assiut University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100553459","phase-4-comparison-of-the-antiplatelet-efficacy-of-aspirin-combined-with-clopidogrel-and-aspirin-combined-with-half-dose-ticagrelor-in-patients-with-unruptured-intracranial-aneurysms-with-normal-cyp2c19-metabolizer-phenotype-100553459","NCT06486363","Comparison of the Antiplatelet Efficacy of Aspirin Combined With Clopidogrel and Aspirin Combined With Half-dose Ticagrelor in Patients With Unruptured Intracranial Aneurysms With Normal CYP2C19 Metabolizer Phenotype","Inclusion Criteria:\n\n1. Patients with unruptured intracranial aneurysms who are scheduled for stent-assisted embolization;\n2. mRS score less than or equal to 2 on admission;\n3. Normal CYP2C19 metabolizer genotype;\n4. Age 20 or above, 70 or below, regardless of gender;\n5. The subject or the entrusted family member voluntarily signed the informed consent for this trial\n\nExclusion Criteria:\n\n1. Use of drugs that affect coagulation function or significant abnormalities in platelet\u002Fcoagulation function before admission;\n2. Previous history of cardiovascular and cerebrovascular disease;\n3. Complications of major organ dysfunction, chronic inflammatory diseases or malignant tumors at admission;\n4. Known allergy or contraindication to heparin, aspirin, clopidogrel, or ticagrelor;\n5. Patients with any severe or active pathological bleeding;\n6. Pregnant and lactating female;\n7. Those deemed unsuitable to participate in this trial by the responsible physician","20 Years","70 Years",{"count":84,"type":20},196,[23],"The goal of this clinical trial is to compare the antiplatelet efficacy of aspirin combined with clopidogrel and aspirin combined with half-dose ticagrelor in in patients with unruptured intracranial aneurysms with normal CYP2C19 metabolizer phenotype. The main questions it aims to answer are:\n\nIf aspirin combined with half-dose ticagrelor is comparable to or better than aspirin combined with clopidogrel? What medical problems do participants have when taking aspirin combined with half-dose ticagrelor? Researchers will compare aspirin combined with half-dose ticagrelor to aspirin combined with clopidogrel to see if aspirin combined with half-dose ticagrelor works to treat patients with unruptured intracranial aneurysms received endovascular treatment.\n\nParticipants will:\n\nTake aspirin combined with half-dose ticagrelor or aspirin combined with clopidogrel every day for 6 months Visit the clinic 1 month and 6 months for checkups and tests",[88,27],"Intracranial Aneurysms","2024-07-26",{"date":91,"type":32},"2024-07-29",{"date":93,"type":20},"2024-08-01",{"date":95,"type":20},"2027-07-31",{"name":97,"class":39},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"]